Laplace Interventional Closes Financing Round for Tricuspid Valve Technology

March 16, 2025—Laplace Interventional, Inc. announced it has closed a Series C financing round of $22 million. The company stated it plans to use the funds to complete an early feasibility study (EFS) of its transcatheter tricuspid valve replacement (TTVR) technology for the treatment of tricuspid regurgitation (TR) and to work toward approval of a pivotal study.

The company has enrolled 22 patients in the United States (largely as part of the United States EFS) and 25 patients globally, with encouraging results, noted the press release. In February 2024, the company announced the completion of the first-in-human procedure with the TTVR device as part of the EFS.

Brandon Jones, MD, interventional cardiologist and Medical Director of Structural Heart at Providence St. Vincent Medical Center in Portland, Oregon, discussed his experience in the company’s press release.

“So far we have treated three patients in the Laplace EFS, and all were discharged home within 1 to 2 days and are doing well,” commented Dr. Jones. “This was our first experience with a dedicated TTVR platform, and we are highly impressed with the intuitive deployment, imaging requirements, and overall ease of use of the Laplace system in a variety of challenging anatomies.”

Laplace Interventional’s TTVR device is in its development phase and is not approved or cleared by the FDA or any other regulatory body in any region of the world, advised the company.

The company stated that the Series C financing round was led by an undisclosed global strategic investor along with participation from two new investors: Aphelion Cardeation and Unorthodox Ventures. Existing investors Engage Venture Partners, JWC Venture, and Features Capital participated in the round. The company also announced the addition of Ned Scheetz, Founding Managing Partner at Aphelion Capital to its Board of Directors.